Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Maria Kondrup; Louise Raunkilde; Inge Marie Svane; Henrik Schmidt; Lars Bastholt

Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Translated title of the contribution: Immunotherapy is cancer treatment with a novel side-effect profile

Maria Kondrup, Louise Raunkilde, Inge Marie Svane, Henrik Schmidt, Lars Bastholt

Department of Clinical Medicine

Abstract

Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.

Translated title of the contribution	Immunotherapy is cancer treatment with a novel side-effect profile
Original language	Danish
Article number	V05170365
Journal	Ugeskrift for Laeger
Volume	179
Number of pages	5
ISSN	0041-5782
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/immunterapi-er-kraeftbehandling-med-en-helt-ny-bivirkningsprofil

Cite this

@article{b49ec0c1affa4a0baa4b325928ccf626,

title = "Immunterapi er kr{\ae}ftbehandling med en helt ny bivirkningsprofil",

abstract = "Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.",

keywords = "Antibodies, Monoclonal/adverse effects, Antineoplastic Agents, Immunological/adverse effects, CTLA-4 Antigen/antagonists & inhibitors, Chemical and Drug Induced Liver Injury/etiology, Drug-Related Side Effects and Adverse Reactions/diagnostic imaging, Endocrine System Diseases/chemically induced, Gastrointestinal Diseases/chemically induced, Humans, Immunotherapy/adverse effects, Lung Diseases/chemically induced, Mobile Applications, Neoplasms/drug therapy, Practice Guidelines as Topic, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Skin Diseases/chemically induced, Tomography, X-Ray Computed",

author = "Maria Kondrup and Louise Raunkilde and Svane, {Inge Marie} and Henrik Schmidt and Lars Bastholt",

year = "2017",

language = "Dansk",

volume = "179",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

AU - Kondrup, Maria

AU - Raunkilde, Louise

AU - Svane, Inge Marie

AU - Schmidt, Henrik

AU - Bastholt, Lars

PY - 2017

Y1 - 2017

N2 - Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.

AB - Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.

KW - Antibodies, Monoclonal/adverse effects

KW - Antineoplastic Agents, Immunological/adverse effects

KW - CTLA-4 Antigen/antagonists & inhibitors

KW - Chemical and Drug Induced Liver Injury/etiology

KW - Drug-Related Side Effects and Adverse Reactions/diagnostic imaging

KW - Endocrine System Diseases/chemically induced

KW - Gastrointestinal Diseases/chemically induced

KW - Humans

KW - Immunotherapy/adverse effects

KW - Lung Diseases/chemically induced

KW - Mobile Applications

KW - Neoplasms/drug therapy

KW - Practice Guidelines as Topic

KW - Programmed Cell Death 1 Receptor/antagonists & inhibitors

KW - Skin Diseases/chemically induced

KW - Tomography, X-Ray Computed

M3 - Tidsskriftartikel

C2 - 28992844

SN - 0041-5782

VL - 179

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V05170365

ER -

Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this